Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
European Journal of Pain (London, England)|October 4, 2005
The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trialSøren H Sindrup, Ana Graf, Nikolaos Sfikas
Alzheimer'S Research & Therapy|January 31, 2014
Active immunotherapy options for Alzheimer's diseaseBengt Winblad, Ana Graf, Marie-Emmanuelle Riviere, et al.
The International Journal of Neuroscience|September 7, 2013
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patientsRajeev Kumar, Robert A Hauser, Joseph Mostillo, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 24, 2016
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studiesClaudia Trenkwalder, Fabrizio Stocchi, Werner Poewe, et al.
Dementia and Geriatric Cognitive Disorders Extra|December 14, 2011
A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's diseaseYu Nakamura, Yukimichi Imai, Masahiro Shigeta, et al.
Alzheimer'S Research & Therapy|April 29, 2015
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's diseaseMartin R Farlow, Niels Andreasen, Marie-Emmanuelle Riviere, et al.
Alzheimer'S Research & Therapy|March 6, 2023
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's diseaseAngelika Caputo, Amy Racine, Ines Paule, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 12, 2025
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meetingRonald C Petersen, Ana Graf, Chris Brady, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b studyRik Vandenberghe, Marie-Emmanuelle Riviere, Angelika Caputo, et al.
The Lancet. Neurology|June 9, 2012
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human studyBengt Winblad, Niels Andreasen, Lennart Minthon, et al.
Pageof 3